Associate Director, Scientific Communications

Associate Director, Scientific Communications Who We Are: Xenon Pharmaceuticals (NASDAQ:XENE https://www.nasdaq.com/market-activity/stocks/xene) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team. What We Do: We are advancing an exciting product pipeline https://xenon-pharma.com/pipeline to address indications with high unmet medical need, including epilepsy, depression and pain. Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026. Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication. We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial. In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting, and continue to advance an early-stage pipeline of novel therapeutic candidates. In 2025, we initiated Phase 1 trials for XEN1701 (targeting Nav1.7) and XEN1120 (targeting Kv7). Nav1.7 and Kv7 are important pain targets, and data from these Phase 1 studies are expected in 2026 to support Phase 2 proof-of-concept studies in acute pain. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations. About the Role: We are seeking an Associate Director, Scientific Communications to support the development and execution of field medical and congress materials for our epilepsy and neuropsychiatry programs, while contributing to broader Medical Affairs priorities across the Xenon pipeline. This role plays a central part in shaping scientifically rigorous, compliant, and strategically aligned materials that engage and educate health care professionals. The Associate Director, Scientific Communications will support the development, review, and approval of scientific content, ensuring alignment with key Medical Affairs and cross-functional platforms, strategic objectives, and tactical plans. Success in this role requires a strong scientific foundation paired with the ability to distill complex neuroscience into scientifically accurate, clear, and compelling narratives tailored for diverse audiences. In addition, you must be a highly collaborative scientific or clinical professional who thrives in a dynamic, fast-paced environment and is committed to operational excellence. This position reports to the Director of Scientific Communications and operates within a multidisciplinary team, interfacing with cross-functional internal stakeholders and external experts. Your contributions will directly shape how Xenon communicates scientific insights, supports strategic initiatives, and advances its programs in epilepsy and neuropsychiatric disorders. This role will be based out of Boston, MA, USA in our Needham office. Hybrid positions require a minimum of two onsite days per week. On-site positions require up to five on-site days per week. RESPONSIBILITIES: - Support the development of fi ... (truncated, view full listing at source)